Evidence map›Paper›PMID 24648609›Full record

ArticleDisease markers2014

Clinical significance of survivin expression in patients with urothelial carcinoma.

Hsin-An Chen, Chih-Ming Su, Hsiao-Yen Hsieh, Chun-Liang Tung, Cheng-Da Hsu, Yuan-Hung Wang, Cheng-Huang Shen

Open access · hybridAbstract read
In one paragraph

Article in Disease markers, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Survivin -31 G/C polymorphism might contribute to colorectal cancer (CRC) risk: a meta-analysis.International journal of clinical and experimental medicine · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Hsin-An ChenDivision of General Surgery, Department of Surgery, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan ; Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, 250 Wu-Hsing Street, Taipei 110, Taiwan.
Chih-Ming SuDivision of General Surgery, Department of Surgery, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan ; Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, 250 Wu-Hsing Street, Taipei 110, Taiwan.ORCID 0000-0002-1035-4238
Hsiao-Yen HsiehDepartment of Biomedical Research, Chiayi Christian Hospital, Chiayi 600, Taiwan.
Chun-Liang TungDepartment of Pathology, Chiayi Christian Hospital, Chiayi 600, Taiwan.
Cheng-Da HsuDepartment of Biomedical Research, Chiayi Christian Hospital, Chiayi 600, Taiwan.
Yuan-Hung WangGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, 250 Wu-Hsing Street, Taipei 110, Taiwan ; Division of General Surgery, Department of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan.
Cheng-Huang ShenDepartment of Urology, Chiayi Christian Hospital, 539 Chung Hsiao Road, Chiayi 600, Taiwan ; Tainan University of Technology, Tainan City 71002, Taiwan.
Chia-Yi Christian Hospital · TWTaipei Medical University-Shuang Ho Hospital · TWTainan University of Technology · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSurvivin is a member of the inhibitors of apoptosis protein family that plays an important role in carcinogenesis. Here, we examined the association between survivin expression and clinical outcome in urothelial carcinoma of the bladder (UCB).

methodsA total of 56 histopathologically confirmed UCB patients were recruited from the Department of Urology of Chiayi Christian Hospital from August 2007 to May 2009. Immunohistochemistry (IHC) was used to detect the survivin expression in tumor tissues. The -31 C/G polymorphism in survivin promoter region was determined by polymerase chain reaction-restricted fragment length polymorphism.

resultsThe frequency of high survivin expression was significantly higher in muscle-invasive tumors (66.6%) than in non-muscle-invasive tumors (34.2%) (P = 0.042) and in poorly differentiated (85.7%) tumors than in moderately differentiated tumors (30.8%) (P = 0.0014). The higher frequency of risk genotypes (C/C and C/G) was found in the median (72.7%) and high (68.0%) survivin expression groups. The multivariate analysis showed that a high survivin expression level was a potential predictive biomarker of poor overall survival (P = 0.02).

conclusionOur results suggest that the high survivin expression was associated with tumor stage and grade and may present a predictive marker of overall survival in UCB.

Indexed as

AgedBiomarkers, TumorCarcinoma, Transitional CellDisease-Free SurvivalEpitheliumFemaleHumansInhibitor of Apoptosis ProteinsKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisProportional Hazards ModelsRetrospective StudiesSurvivinUrinary Bladder NeoplasmsBiomarkers, TumorBIRC5 protein, humanInhibitor of Apoptosis ProteinsSurvivin

Identifiers

PMID24648609
PMCPMC3933524
OpenAlexW2028460922

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.